List view / Grid view
AbbVie releases promising results from its Phase III trial of…
AbbVie releases promising results from its Phase III trial of atogepant (Qulipta™) for preventative treatment of chronic migraine.
AbbVie announced the initiation of a Phase III clinical trial…
26 June 2014 | By AbbVie
AbbVie announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888)...
Biogen Idec and AbbVie announced positive top-line results from the…
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
AbbVie has named Michael Severino, M.D. its new Executive Vice…
19 May 2014 | By AbbVie
AbbVie has named Michael Severino, M.D. its new Executive Vice President, Research and Development and Chief Scientific Officer...
Amgen announced top-line results of the Phase 3 Aranesp® RED-HF®…
16 January 2013 | By Amgen
Amgen announced top-line results of the Phase 3 Aranesp® RED-HF® Trial...
Study results presented at American Society of Nephrology's Kidney Week...
3 November 2012 | By Amgen
Study results presented at American Society of Nephrology's Kidney Week...
Exploratory biomarker analysis results...
16 May 2012 | By Amgen
Exploratory biomarker analysis results...
"Mike brings broad experience and immense expertise to his new…
14 February 2012 | By Amgen
"Mike brings broad experience and immense expertise to his new role..."
